AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity by Leung, THY et al.
Title AMPK Activators Suppress Cervical Cancer Cell Growth throughInhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity
Author(s) Kwan, HT; Chan, DW; Cai, C; Mak, SL; Yung, MH; Leung, THY;Wong, GW; Cheung, ANY; Ngan, HYS
Citation PLoS ONE, 2013, v. 8, p. e53597
Issued Date 2013
URL http://hdl.handle.net/10722/180191
Rights Creative Commons: Attribution 3.0 Hong Kong License
AMPK Activators Suppress Cervical Cancer Cell Growth
through Inhibition of DVL3 Mediated Wnt/b-Catenin
Signaling Activity
H. T. Kwan1, David W. Chan1*, Patty C. H. Cai1, Celia S. L. Mak1, Mingo M. H. Yung1, Thomas H. Y. Leung1,
Oscar G. W. Wong2, Annie N. Y. Cheung2, Hextan Y. S. Ngan1*
1Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P. R. China, 2Department of Pathology, LKS Faculty
of Medicine, The University of Hong Kong, Hong Kong SAR, P. R. China
Abstract
Recent evidence has suggested that AMPK activators may be applied as therapeutic drugs in suppressing cancer cell
growth. However, the molecular mechanism of their suppressive function in cancer cells is still unclear. Here we show that
AMPK activators impair cervical cancer cell growth through the reduction of DVL3, a positive regulator in Wnt/b-catenin
signaling and an oncogenic player in cervical cancer tumorigenesis. By western blot and immunohistochemical analyses, we
demonstrated that DVL3 was frequently upregulated and significantly associated with elevated b-catenin (P= 0.009) and
CyclinD1 (P= 0.009) expressions in cervical cancer. Enforced expression of DVL3 elevated b-catenin and augmented cervical
cancer cell growth, verifying that DVL3-mediated Wnt/b-catenin activation is involved in cervical cancer oncogenesis. On
the other aspect, we noted that the cervical cancer cell growth was remarkably suppressed by AMPK activators and such cell
growth inhibition was in concomitant with the reduction of DVL3 protein level in dose- and time-dependent manners.
Besides, impaired mTOR signaling activity also reduced DVL3 expression. In contrast, co-treatment with Compound C (AMPK
inhibitor) could significantly abrogate metformin induced DVL3 reduction. In addition, co-treatment with AM114 or MG132
(proteosomal inhibitors) could partially restore DVL3 expression under the treatment of metformin. Further in vivo
ubiquitination assay revealed that metformin could reduce DVL3 by ubiquitin/proteasomal degradation. To our knowledge,
this is the first report showing the probable molecular mechanisms of that the AMPK activators suppress cervical cancer cell
growth by impairing DVL3 protein synthesis via AMPK/mTOR signaling and/or partially promoting the proteasomal
degradation of DVL3.
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Introduction
Cervical cancer is one of the most common gynecological
cancers worldwide. To date, the most well-known cause of cervical
cancer is the human papillomavirus (HPV) infection. Persistent
HPV infection promotes the development of precancerous lesions
to cervical cancer [1]. However, HPV infection alone is not
sufficient to transform epithelial host cells to cancer cells. Thus,
other factors, such as the up-regulation of oncogenes and aberrant
activation of related signaling pathways, may be involved in
cervical carcinogenesis [2]. Recent evidences have shown that
aberrant activation of Wnt/b-catenin signaling is crucially in-
volved in cancer development [3,4,5]. The accumulation of b-
catenin is the hallmark in causing aberrant activation of Wnt/b-
catenin signaling which is closely associated with the carcinogen-
esis of uterine cervix [6,7,8,9], and particularly in invasive cervical
carcinomas [10]. Thus, targeting this pathway may be a promising
approach in molecular therapy of this disease.
AMP-activated protein kinase (AMPK) is a master regulator of
cellular energy system [11]. Activated AMPK activity impairs
mechanistic target of Rapamycin (mTOR) signaling and its
corresponding p70S6 kinase and 4E-BP1 activity [12], thereby
inhibiting protein synthesis [13,14] and cell growth. Therefore, it
is not surprising that low AMPK activity favors carcinogenesis
[15,16]. To this end, numerous pharmaceutical AMPK activators
such as A23187, A769662, 5-aminoimidazole-4-carboxamideribo-
nucleoside (AICAR) and metformin have recently been shown to
exert anti-tumor effects in numerous human cancers
[17,18,19,20,21,22,23]. Particularly, metformin has been used in
several ongoing clinical trials [24,25,26,27]. However, the
molecular mechanisms for the anti-tumor effects of these AMPK
activators have not yet been clearly elucidated.
In this study, we showed that DVL3 was significantly
upregulated and was correlated with Wnt/b-catenin activity in
cervical cancer. More importantly, we are the first to provide
evidence that AMPK activators inhibit cervical cancer cell growth
through impairing DVL3-mediated Wnt/b-catenin signaling in
cervical cancer cells. We showed that the inhibition of AMPK/
mTOR-mediated protein synthesis and the enhancement of
proteasomal degradation were the molecular mechanisms in the
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reduction of DVL3 exhibited by AMPK activators. Our findings
implicate the importance of DVL3 in the cervical cancer
oncogenesis and highlight the therapeutic value of targeting
DVL3 by AMPK activators in cervical cancer treatment.
Materials and Methods
Cell culture
Five cervical cancer cell lines (HeLa, SiHa, C33A, CaSki and
C41) (American Type Culture Collection, Rockville, MD) (cell
lines authentication was done by in-house STR DNA profiling
analysis) and two immortalized cervical epithelial cell lines (NC104
and NC105) [6] (gift from Prof. George. Tsao, Department of
Anatomy, The University of Hong Kong) were used in this study.
All cell lines were grown at 37uC in 5% CO2 in minimum
essential medium or Dulbecco’s modified Eagle medium (Gibco-
BRL, Gaithersburg) with 10% fetal bovine serum (Gibco) and 1%
Penicillin-Streptomycin (Gibco).
Plasmids and cell transfection
The GFP-tagged-DVL3 expressing construct was used for
GFP/DVL3 protein expression [28], while the pEGFP-C1
plasmid was used as negative control. The pCMV2-Flag/DVL3
was used for TOP/FOP luciferase reporter assay, while both
pSuper8XTOPFlash and pSuper8XFOPFlash constructs were
kindly provided by Dr. R. Moon (University of Washington,
Washington, USA). LipofectAMINETM 200 (Invitrogen Life
Technologies, Carlsbad, CA) was used for cell transfection
according to the manufacturer’s protocols. For the establishment
of GFP-DVL3 stably expressing cells, transfected cells were
selected with G418 for 2 weeks and verified by western blot
analysis.
RNA extraction and Quantitative reverse transcriptase–
PCR
Total RNA was extracted by TRIzol reagent (Invitrogen)
according to the manufacturer’s instruction. Complementary
DNA was synthesized using reverse transcription reagent kit
(Applied Biosystems, Foster City). The expression of DVL3 was
evaluated by quantitative reverse transcriptase-PCR (q-PCR) in an
ABI PRISMTM 7500 system (Applied Biosystems) using TaqmanH
Gene expression Assays; human DVL3 (Assay ID:
Hs00610263_m1). The human 18S rRNA (Assay ID:
Hs99999901_m1) was used as an internal control.
Figure 1. DVL3 and b-catenin are frequently up-regulated and associated with augmented Wnt/b-catenin signaling activity in
cervical cancer. (A) Western blot analysis showed that only the level of DVL3 but not DVL1 and DVL2 was significantly up-regulated in cervical
cancer cell lines when compared with the normal cervix cell lines. (B) Real time q-PCR revealed the mRNA of DVL3 was obviously higher among
cervical cancer cell lines when compared with the normal cervix cell lines. The value of NC105 was used to normalize other cell lines. (C)
Immunohistochemical analysis showed that both DVL3 and b-catenin were upregulated on cervical cancer tissues when compared with normal
cervix samples. DVL3 was distributed in the cytoplasmic region whereas b-catenin was located in both the cytoplasmic and nuclear regions.
(Magnification: 20x) (D) Luciferase reporter assay revealed that transient transfection of DVL3-expressing plasmid could increase b-catenin
transcriptional activity in HEK293 cells.
doi:10.1371/journal.pone.0053597.g001
AMPK Suppresses Cervical Cancer Cell Growth
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e53597
Protein Extraction, Western blotting and
Immunohistochemical (IHC) analyses
Protein lysate was extracted by lysing cells pellet with 1x lysis
buffer (10X lysis buffer (Cell Signaling Technology, Danvers, MA,
USA), 1:100 PMSF, protease inhibitor and distilled water). For
western blot analysis, samples containing a fixed amount of protein
were separated by SDS-PAGE and electroblotted to the Hybond-
P membranes (Amersham Pharmacia Biotech, Cleveland, OH,
USA). Membranes were then blotted with 5% skimmed milk for
30 minutes and incubated with primary antibodies; anti-
pp70S6kinase, anti-p70S6 kinase, anti-pAMPKa, anti-AMPKa,
anti-CyclinD1 (Cell signaling Technology), anti-DVL1, anti-
DVL2, anti-DVL3, anti-GFP (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and anti-b-catenin (BD Biosciences, San Jose,
CA, USA) overnight at 4uC. Anti-mouse or anti-rabbit secondary
antibody conjugated to horse radish peroxide (Amersham
Pharmacia Biotech, OH) was used and visualized by enhanced
chemiluminescence (Amersham). For immunohistochemical anal-
ysis, cervical cancer tissue array (CXC1021) (5 cases of normal
cervix/cervicitis and 97 cases cervical cancers) (Pantomics Inc,
CA, USA) were used for immunohistochemical staining for DVL3,
b-catenin and CyclinD1. The sections were immunostained with
primary anti-DVL3(1:200 dilution)(NB110-59941, Novus Biologi-
cals, Littleton, CA USA), anti-b-catenin (BD Biosciences)(1:200
dilution) and anti-CyclinD1(1:100 dilution)(H-295, Santa Cruz
Biotehcnology). Incubation with Tris-buffered saline was used as
negative controls. Their expression levels were scored manually by
multiplying the percentage of the proportion of immunopositive
staining area (0–100%) and the intensity of staining (+1, weak; +2,
moderate; +3, intense; and +4, very intense). The fold change of
each gene was calculated by dividing its expression level of each
cancer sample by the mean value of its expression level of normal
cervix/cervicitis. The cutoff point (number of folds) of each gene
was then determined by its expression levels and statistical
significance. All tissue section were examined and scored in-
dependently by two investigators.
Luciferase Reporter Assay
HEK293 cells were transiently transfected with 0, 50, 100, and
200 ng of pCMV2-Flag/DVL3 as well as either a pSuper8XTOP-
Flash or pSuper8XFOPFlash luciferase reporter construct. All
transfections were normalized with pcDNA3.1 (+) vector. The
luciferase activity was determined using the Dual-Luciferase
Reporter Assay System (Promega). Transfection efficiencies were
normalized with Renilla luciferase activity. All experiments were
performed in triplicate and in 3 independent experiments.
In Vivo Ubiquitination Assay
The procedure was described as previously [29]. Briefly, C33A
or Hela cells were seeded onto 100 mm culture plates. The
pcDNA-HA(Ub)8 was transient transfected into the above cell
types respectively using Lipofeactamin 2000 transfection kit
(Invitrogen). The cell lysate was harvested by using NET lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl and 5 mM EDTA)
with 1% NP40, pH 8.0, 0.1 mM PMSF, and 1 mM Complete
TM protease inhibitor cocktail (Roche)) on the cell pellet. One mg
of cell lysate was incubated with 1 mg of mouse anti-IgG and anti-
DVL3 (Santa Cruz) at 4uC. After incubation, 40 ml of Protein A/
G Plus-Agarose beads (Santa Cruz) were added to each sample
and mixed by rotating overnight at 4uC. After centrifugation, the
beads were washed four times with NET lysis buffer, followed by
addition of sample buffer containing DTT and boiled for 10 min
prior to electrophoresis. The proteasome inhibitors, MG132 and
AM114, were obtained from Calbiochem (La Jolla, CA).
Cell viability assay
Cell proliferation kit (XTT)(Roche) was used to measure cell
viability for 5 days according to the manufacturer’s protocol.
Three independent experiments were performed in triplicate.
Table 1. Clinicopathological correlation of DVL3 expression
in cervical cancer tissue array (CX1021) (Pantomics, CA, USA).
Characteristics Total DVL3 expression (Fold change)
#5 folds .5 folds P
All cases 96 35 (36.5%) 61 (63.5%)
Stage
Early 64 21 (32.8%) 43 (67.2%)
Late 32 14 (43.8%) 18 (56.2%) 0.369
Grade
Low 54 21 (38.9%) 33 (61.1%)
High 37 12 (32.4%) 25 (67.6%) 0.658
Metastasis
No 70 23 (32.9%) 47 (67.1%)
Yes 26 12 (46.2%) 14 (53.8%) 0.243
b-catenin
#7 folds 60 28 (46.7%) 32 (53.5%)
.7 folds 36 7 (19.4%) 29 (80.6%) 0.009*
CyclinD1
#2 folds 38 20 (52.6%) 18 (47.4%)
.2 folds 58 15 (25.9%) 43 (74.1%) 0.009*
doi:10.1371/journal.pone.0053597.t001
Table 2. Clinicopathological correlation of b-catenin
expression in cervical cancer tissue array (CX1021) (Pantomics,
CA, USA).
Characteristics Total b-catenin expression (Fold change)
#7 folds .7 folds P
All cases 96 60 (62.5%) 36 (37.5%)
Stage
Early 64 43 (67.2%) 21 (32.8%)
Late 32 17 (32.8%) 15 (46.9%) 0.189
Grade
Low 54 38 (70.4%) 16 (29.6%)
High 37 18 (48.6%) 19 (51.4%) 0.049*
Metastasis
No 70 46 (65.7%) 14 (53.8%)
Yes 26 14 (53.8%) 12 (46.2%) 0.345
DVL3
#5 folds 35 28 (80%) 7 (20%)
.5 folds 61 32 (52.5%) 29 (47.5%) 0.009*
CyclinD1
#2 folds 38 30 (78.9%) 8 (21.1%)
.2 folds 58 30 (51.7%) 28 (48.3%) 0.009*
doi:10.1371/journal.pone.0053597.t002
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Clonogenic assay
Cells were allowed to grow for 2 weeks. After 2 weeks, medium
was removed followed by incubation with methanol for 30 min-
utes and then stained with crystal violet for 1 hour. After the
staining, cells were washed with PBS. Triplication of each sample
and three independent experiments were performed and the
number of cells was counted by the Gel-Doc system.
Data analysis
Student’s t test (for parametric data) and the Mann-Whitney test
(for non-parametric data) were used for analysis. The clinicopath-
ological analysis between the expression of DVL3, b-catenin,
CyclinD1 and clinical parameters was analyzed by Crosstabs and
Pearson Chi-Square test using the SPSS 13.0 software (SPSS,
Chicago, IL). All data were expressed as mean 6 SD. A P-value of
less than 0.05 was considered as significant.
Figure 2. Ectopic expression of DVL3 enhances Wnt/b-catenin signaling activity and cell proliferation in cervical cancer cells. (A)
Western blot showed that stably over-expressing GFP-DVL3 elevated expression of b-catenin in C33A (C-G25 and C-G28) and SiHa (S-G18 and S-G20).
(B) XTT assay revealed a significant increase of cell proliferation in cervical cancer cells with stable expression of GFP-DVL3 (C-G24 and C-G28; P,0.05)
(S-G18 and S-G20; P,0.05). (C) Clonogenic assay showed that twice and thrice the number of colonies were found in GFP-DVL3 ectopically expressing
C33A cells (C-G25 and C-G28) (P,0.05) and SiHa cells (S-G18 and S-G20) (P,0.05) as compared with their vector controls.
doi:10.1371/journal.pone.0053597.g002
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Results
DVL3 is frequently upregulated in cervical cancer cells
Emerging evidences have shown that DVLs are able to up-
regulate b-catenin and promote cell growth in colorectal cancer
[30], malignant pleural mesothelioma [31] and non-small-cell lung
cancer [32] etc. We thus examined the expression pattern of DVLs
(DVL1, DVL2 and DVL3) in cervical cancer cell lines by western
blot analysis. Our data demonstrated that DVL3 but neither
DVL1 nor DVL2 was significantly up-regulated in a panel of
cervical cancer cell lines (Hela, SiHa, CaSki, C33A and C41)
when compared with immortalized cervix cell lines (NC104 and
NC 105) (Figure 1A), suggesting that DVL3 is dominantly
upregulated in cervical cancer cells. We next examined the
mRNA level of DVL3 in these cell lines by real time quantitative
reverse transcription PCR (q-PCR). Similarly, the DVL3 mRNA
levels were significantly higher in cervical cancer cell lines as
compared with the normal immortalized cervix cell lines
(Figure 1B). Collectively, these findings indicate that DVL3 is
the major isoform of DVLs frequently up-regulated in cervical
cancers cells.
Overexpression of DVL3 and b-catenin in cervical cancer
To study the significance of DVL3 and b-catenin in cervical
cancer, we examined the expressions of DVL3 and b-catenin on
a cervical cancer tissue array (CX1021) using immunohistochem-
ical (IHC) analysis. The immunoreactivity of DVL3 was only
observed in the cytoplasm whereas b-catenin localized in both
nuclei and cytoplasmic regions of both normal and cervical cancer
cells (Figure 1C). IHC analysis showed that remarkable increased
expressions of DVL3 and b-catenin were observed in cervical
tumor sections as compared with the normal cervix sections
(Tables 1 and 2). Statistical analysis showed that high expression of
DVL3 (rank.5 folds) was significantly correlated with high level of
b-catenin (rank.7 folds; P= 0.009)(Table 1). However, there was
no significant association between DVL3 expression and other
clinical parameters, such as tumor stages (P=0.369), grading
(P=0.658), metastasis (P=0.243), b-catenin (P=0.009) and
CyclinD1 (P=0.009). On the other hand, the up-regulation of
b-catenin (rank .7 folds) was significantly associated with high
grade tumors (P=0.049) and over-expression of CyclinD1
(P=0.009) but there was no significant correlation with tumor
stages (P=0.189) and metastasis (P=0.345) (Table 2). Taken
together, these findings indicate that the increased expression of
DVL3 is correlated with b-catenin which is involved in cervical
cancer development.
DVL3 enhances proliferation of cervical cancer cells
DVLs are important signal transduction molecules mediating
Wnt/b-catenin signaling activity to control cell growth. To address
whether DVL3 could promote Wnt/b-catenin signaling activity,
the dual luciferase reporter assay was performed. Transfection of
DVL3-expressing plasmid into HEK293 cells increased b-catenin
transcriptional activity in a dose-dependent manner (Figure 1D),
suggesting that DVL3 is a positive regulator of the Wnt/b-catenin
signaling cascade. Next, to investigate whether DVL3 promotes
cell proliferation via activation of Wnt/b-catenin pathway in
cervical cancer, two cervical cancer cell lines (C33A and SiHa)
with stably expression of DVL3 were established using human
GFP-tagged DVL3 expressing plasmid. Western blot analysis
revealed that b-catenin was significantly elevated in GFP-DVL3
Figure 3. AMPK activators reduce DVL3 in cervical cancer cells. (A) Upon treatment of AICAR, approximately 80% reduction of DVL3 level was
observed among C33A, C41 and CaSki. (B) Upon treatment of A769662 at different doses (0, 50 and 100 mM), a 20-30% and 80%–100% reduction of
DVL3 in SiHa and C33A could be observed respectively. (C) Upon treatment with A23187 at different doses (0, 1.25 and 2.5 mM) for twenty hours,
C33A and SiHa cells showed 80–90% reduction of DVL3 expression in a dose-dependent manner. (D) Upon treatment of 1.25 mM A23187, the
decrease of DVL3 could be observed after 10 and 12 hours in C33A and CaSki respectively, while a further 100% reduction of DVL3 was observed at
12 and 24 hours for both cell lines. (E) Upon treatment of metformin, 60–80%reduction of DVL3 was observed in Hela, SiHa, CaSki, C41 and C33A in
a dose-dependent manner.
doi:10.1371/journal.pone.0053597.g003
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Figure 4. AMPK activation impairs cervical cancer cell growth through the reduction of DVL3. (A) Real time q-PCR analysis demonstrated
that metformin had no effect on the expression of DVL3 mRNA expression in C33A and HeLa cells. (B) Western blot analysis revealed that compound
C could abate the decrement of DVL3 mediated by metformin. (C) XTT cell proliferation assay showed a significant reduction of cell proliferation in
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stable clones in C33A (C-G25 and C-G28) and SiHa (S-G18 and
S-G20) (Figure 2A). Functionally, XTT cell proliferation assay
revealed that ectopic expression of DVL3 significantly enhanced
cell proliferation in GFP-DVL3 stable clones of SiHa (P,0.05)
and C33A (P,0.001) cells (Figure 2B). In addition, clonogenic
assay revealed that there were 2-3 fold increase in the number of
colonies in SiHa cells stably expressing GFP-DVL3 (S-G18 and S-
G20) (P,0.05) and C33A cells (C-G25 and C-G28) (P,0.05)
respectively as compared with their vector controls (Figure 2C).
Collectively, these findings suggest that DVL3 enhances Wnt/b-
catenin signaling activity and promotes the proliferation of cervical
cancer cells.
AMPK activators reduce DVL3 in cervical cancer cells
Numerous studies have demonstrated that AMPK activators
can inhibit cell growth in cancers, particularly in cervical cancer in
vitro [21,33,34]. Therefore, we examined the effect of AMPK
activators on the expression of DVL3 and its related Wnt/b-
catenin signaling activity in cervical cancer cells. AICAR
treatment resulted in significant reduction of DVL3 levels in three
cervical cancer cell lines (Figure 3A). Another AMPK activator,
A23187, activates AMPK through its upstream kinase (CaMKK)
by increasing the cytosolic calcium level [20], also reduced DVL3
expression in C33A and SiHa cells in a dose-dependent manner
(Figure 3C). In order to further assess the effect of A23187 on
DVL3 expression, C33A and CaSki were treated with 1.25 mM
A23187 and harvested at different time-points. Decrement of
DVL3 was observed after 10 and 12 hours in C33A and CaSki
respectively and no DVL3 was observed after 12 and 24 hours for
both cell lines (Figure 3D). To further assess whether the reduction
of DVL3 mediated by AMPK activators is a universal process, two
well-known AMPK activators, A769662 and metformin, were
used. A769662 is a thienopyridone which activates AMPK
through interacting with the a- and b-subunit of AMPK. Upon
A769662 treatment, DVL3 expression was abolished in a dose-
dependent manner in SiHa and C33A (Figure 3B). In addition,
metformin is a very common AMPK activator as well as a potential
anti-cancer drug [22]. Upon treatment of metformin, several
cervical cancer cell lines displayed differential responses to
metformin and showed depletion of DVL3 in a dose-dependent
C33A (P.0.001), SiHa (P.0.001) and HeLa cells (P.0.001) treated with metformin in a dose-dependent manner. (D) Clonogenic assay showed
a remarkable reduction of the number of colonies formed in HeLa and C33A treated with metformin in a dose-dependent manner.
doi:10.1371/journal.pone.0053597.g004
Figure 5. AMPK activators reduce DVL3 through either inactivation of mTOR activity or increased proteasomal degradation in
cervical cancer cells. (A) Rapamycin inactivated p70S6 kinase activity and aborted protein synthesis of DVL3 in all cervical cancer cell lines (C33A,
C41, CaSki, HeLa and SiHa) in a dose-dependent manner. (B) Proteasomal inhibitor, AM114, restored the reduced DVL3 mediated by metformin in
C33A. (C) Proteasomal inhibitor, AM114, could not restore the reduced DVL3 mediated by metformin in SiHa and HeLa. (D) In vivo ubiquitination
assay showed that DVL3 was degraded as poly-ubiquitinated DVL3 protein ((Ub)n-DVL3) in C33A cell model. C33A cells were transfected with pcDNA-
HA(Ub)8 plasmid. Both MG132 or AM114 and metformin were used to enhance the amount of polyubiquitinated DVL3 protein products ((Ub)n-DVL3).
Cell lysates were incubated with anti-DVL3, and the immunoprecipitates were probed with anti-HA. The same membrane was re-probed with anti-
DVL3 to detect the expression of DVL3.
doi:10.1371/journal.pone.0053597.g005
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manner (Figure 3E), along with no change in the mRNA level of
DVL3 in C33A and HeLa (Figure 4A), suggesting that the
reduction of DVL3 regulated by AMPK activators was associated
with post-transcriptional events. Taken together, these data imply
that AMPK activators can reduce DVL3 and such effect is
a universal process.
AMPK activation is crucial for the reduction of DVL3
mediated by AMPK activators
Although themajor role of AMPKactivators is to activate AMPK
activity, numerous reports have evidenced that some AMPK
activators may exert off-target effects [35,36]. Therefore, it is of
interest to examine whether AMPK activators mediated reduction
of DVL3 is solely dependent on AMPK signaling activity. We used
a potent AMPK inhibitor, compound C, to counteract the effect of
metformin on the AMPK activation. Consistently, reduction of
DVL3 was observed after treatment of metformin in C33A and
SiHa (Figure 4B), yet the decrement of DVL3 was abrogated with
the addition of compoundC. (Figure 4B). These data suggest that the
reduction of DVL3 mediated by metformin is mainly through
AMPK signaling activity.
AMPK activators impair cervical cancer cell proliferation
through reduction of DVL3 and Wnt/b-signaling activity
We have demonstrated that ectopic expression of DVL3 could
enhance cell proliferation in cervical cancer cells. Therefore, to
gain further insight into the function of depleted DVL3 in
minimizing Wnt/b-catenin signaling and cell proliferation medi-
ated by AMPK activators, C33A, SiHa and HeLa cells were
treated with metformin and their proliferation rates were
examined by XTT assay. Our results demonstrated that
metformin significantly repressed cell proliferation in C33A
(P.0.001), SiHa (P.0.001) and HeLa cells (P.0.001)
(Figure 4C). Furthermore, clonogenic assay also revealed that
the number of colonies was reduced by 20 and 50% in C33A and
HeLa cells respectively (Figure 4D). These findings manifest that
the inhibition of cervical cancer cell growth by AMPK activators is
attributed to the reduction of DVL3.
AMPK/mTOR activity is essential for the depletion of
DVL3
AMPK activators are able to activate AMPK and modulate its
downstream cascade, such as the translational control of protein
synthesis through inhibition of mTOR pathway [12,13,14].
Therefore, we reasoned the blockage of AMPK/mTOR activity
can mimic the effects of AMPK activators on the decrement of
DVL3. A mTOR inhibitor (Rapamycin) was employed to inhibit
mTOR activity. Rapamycin suppresses the kinase activities of
mTOR to inactivate p70S6k, thereby abolishing certain protein
translation [37]. Upon treatment of Rapamycin, DVL3 was
reduced in cervical cancer cell lines (C33A, C41, CaSki, HeLa and
SiHa) in a dose-dependent manner. Furthermore, the inactivation
of p70S6k in concomitant with the reduction of DVL3 was
observed in HeLa and SiHa cells treated with 1 nM Rapamycin
(Figure 5A). Taken together, the reduction of protein synthesis
could reduce DVL3 expression in cervical cancer cell lines and
that the decrement of DVL3 mediated by AMPK activators is
mainly through the AMPK/mTOR signaling cascade.
AMPK activators also promote proteasomal degradation
of DVL3
Several lines of evidence have shown that DVLs are tightly
regulated by proteasomal degradation mechanisms in which loss of
factors involved in the ubiquitination pathways leads to DVLs
accumulation [28,38]. Thus, we reasoned that proteasomal
degradation might serve as an alternative mechanism attributed
to AMPK activators mediated DVL3 reduction. We used AM114,
a proteasomal inhibitor, to suppress ubiquitin/proteasomal
degradation. Upon co-treatment with AM114 and metformin,
restored DVL3 expression was observed in C33A but not in SiHa
and HeLa cells (Figure 5B and 5C). The in vivo ubiquitination assay
further demonstrated that DVL3 in C33A cells could be degraded
through ubiquitin/proteasome pathway because the formation of
DVL3-ubiquitinated products was observed upon treatment of
metformin and such DVL3-ubiquitinated products were further
enhanced when co-treatment with either AM114 or MG132
(Figure 5D). These data indicate that the proteasomal degradation
also plays a role in the reduction of DVL3 mediated by AMPK
activators.
Discussion
In this study, we have shown that DVL3 was aberrantly over-
expressed and significantly correlated with increased b-catenin in
cervical cancer. Our data also demonstrated that DVL3 could
promote cervical cancer growth through activating Wnt/b-catenin
signaling pathway. More importantly, we addressed the potential
use of AMPK activators in reducing DVL3 and hence inhibiting
the cervical cancer cell growth. Besides, this is the first report
showing the possible molecular mechanisms of how AMPK
activators impair cervical cancer cell growth through the crosstalk
between AMPK and the Wnt/b-catenin signaling.
Aberrant activation of Wnt/b-catenin signaling pathway has
been documented in various human cancers including cervical
cancer [39]. Indeed, mounting evidences have shown that DVLs
which are positive regulators of the Wnt/b-catenin signaling
pathway are frequently upregulated in a variety of human cancers
[32,40,41,42,43,44,45,46]. The overexpressed DVLs are closely
associated with the increased Wnt/b-catenin activity in human
cancers [31,32,47]. However, very little is known about the
functional roles of DVLs in cervical cancer. Herein, we observed
that DVL3, but neither DVL1 nor DVL2, was significantly up-
regulated and associated with augmented Wnt/b-catenin signaling
activity and cervical cancer cell growth.
Numerous studies have reported that the upstream kinases of
AMPK, like LKB1, is frequently mutated and deleted in lung,
breast and especially cervical cancers [21,48,49], thereby lowering
AMPK activities for cancer cell growth. Indeed, low AMPK
activity is a common event favoring cancer cell growth [15,16].
Thus, AMPK is a crucial target in cancer therapy. We and other
groups have previously demonstrated that several AMPK
activators could suppress cancer cell growth [21,22,50]. However,
the molecular mechanisms of the repression remain largely
unexplored. Previously, Kohno’s group showed that metformin
reduced the protein level of b-catenin through regulating its
phosphorylation-dependent degradation [51]. This gave us a clue
that metformin may regulate upstream regulators of the Wnt/b-
catenin signaling cascade. Herein, we demonstrated that remark-
able reduction of DVL3 could be induced by multiple AMPK
activators, suggesting that AMPK activators universally reduce
DVL3. In line with previous reports on the anti-tumor effect of
metformin through down-regulating the CyclinD1 level in prostate
cancer and breast cancer [52,53], the reduction of DVL3
expression is also in concomitant with the decreased levels of b-
catenin and its downstream target, CyclinD1, which is responsible
for cell cycle control. Surprisingly, metformin only affects the
protein level of DVL3 but not its mRNA, indicating that the
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regulation of DVL3 mediated by AMPK activators relies on post-
transcriptional modification.
As multiple AMPK activators could reduce DVL3, we
speculated that AMPK activity is essential in such regulation. In
order to test whether AMPK activators exert their effects on
DVL3 through the activation of AMPK, an AMPK inhibitor,
compound C, was co-treated with metformin in cervical cancer
cells to counteract the effect of AMPK activation. As expected,
compound C abated the function of metformin in attenuating
DVL3 expression. These findings manifest that AMPK activators
could reduce DVL3 through modulating AMPK activity, and such
effect is not due to AMPK activators’ off-targeted functions.
Indeed, in vitro cell proliferation assays also revealed that the use of
AMPK activators (e.g. metformin) could reduce cell proliferation.
We provide solid evidence that AMPK activators, especially
metformin, exert a down-regulating effect on DVL3 and hence
reduce the expression levels of b-catenin and CyclinD1, and
ultimately attenuate cell proliferation. More importantly, we are
the first to show that AMPK activators exert their anti-pro-
liferative effect through reducing DVL3 and Wnt/b-catenin
signaling activity. AMPK activation plays a requisite role in
suppressing tumor development in cervical cancer. These findings
underscore the therapeutic value of targeting DVL3 using AMPK
activators in cervical cancer treatment.
Activation of AMPK activity suppresses mTOR signaling
through inhibiting p70S6 kinase activity and thereby attenuates
protein translation [37,54,55]. We therefore reasoned that the
suppression of mTOR signaling could affect the translational
efficiency of DVL3. In fact, treatment of an mTOR inhibitor,
Rapamycin, could abolish DVL3 in cervical cancer cell lines. Also,
Rapamycin could lower the expression level of b-catenin,
suggesting that Rapamycin exhibited similar behaviors as AMPK
activators in the reduction of Wnt/b-catenin signaling through
regulating DVL3 expression [56]. On the other hand, we may also
question that the suppression of protein synthesis mediated by
mTOR/p70S6 inhibition may reduce other important cellular
proteins simultaneously. However, the high proliferative capacity
of cervical cancer cells closely relies on Wnt/b-catenin signaling
activity and its associated oncoprotein levels [10,57]. Therefore,
DVL3, a key oncoprotein in activating Wnt/b-catenin signaling,
should have a higher impact on cell growth upon the treatment of
AMPK activators in cervical cancer cells.
Aforementioned, numerous reports have suggested that protea-
somal degradation plays important role in regulating DVLs. For
examples, DVLs are ubiquitinated by different ubiquitin ligases,
such as NEDL1 and KLHL12-Cullin-3 [58,59], or factors
involved in the ubiquitination-degradation such as Prickle-1,
Dapper1, myristoylated Naked2 and Down syndrome critical
region protein (Dscr5) [28,38,60,61]. Therefore, we reasoned that
proteasomal degradation was involved in the reduction of DVL3
induced by AMPK activators. As expected, AMPK activators
mediated down-regulation of DVL3 could be restored after
suppression of proteasomal degradation by AM114 or MG132.
However, such effect was only observed in C33A but not in SiHa,
indicating that proteasomal degradation mechanism only plays
a minor role in the regulation of DVL3 by AMPK activators in
cervical cancer cells.
In conclusion, we revealed the oncogenic role of DVL3 in
augmented Wnt/b-catenin signaling activity in cervical cancer.
More importantly, AMPK activators could suppress over-ex-
pressed DVL3 mainly through attenuation of AMPK/mTOR
mediated protein synthesis and partially regulated by promoting
ubiquitin/proteasome mechanism. Altogether, these findings
underscored the value of AMPK activators as promising anti-
cancer agents in cervical cancer therapy. The understanding of the
regulation of AMPK activators on DVL3 will assist in the
exploration of alternative anti-cancer drugs for clinical usage.
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